Jackson Creek Investment Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jackson Creek Investment Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-70,296	Closed	-$1.76M	–	330
2024 Q3	$1.76M	Buy	70,296 +16,000	+29%	+$390K	0.52%	42
2024 Q2	$1.01M	Sell	54,296 -88	-0.2%	-$1.65K	0.37%	140
2024 Q1	$1.07M	Buy	+54,384	New	+$1.06M	0.38%	120
2023 Q4	–	Sell	-65,607	Closed	-$1.14M	–	333
2023 Q3	$1.14M	Sell	65,607 -47	-0.1%	-$792	0.48%	34
2023 Q2	$924K	Buy	65,654 +4,055	+7%	+$54.3K	0.37%	128
2023 Q1	$663K	Sell	61,599 -10	-0%	-$132	0.28%	199
2022 Q4	$923K	Buy	+61,609	New	+$897K	0.41%	77
2022 Q2	–	Sell	-81,995	Closed	-$815K	–	344
2022 Q1	$815K	Buy	81,995 +4,926	+6%	+$52.2K	0.3%	180
2021 Q4	$907K	Buy	+77,069	New	+$947K	0.32%	175

Other funds holding KNSA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jackson Creek Investment Advisors's KNSA Position: Q4 2024 in Review

Jackson Creek Investment Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 70,296 shares — an estimated $1.76M sold.

Jackson Creek Investment Advisors first reported a position in KNSA in Q4 2021 and held it in 9 quarters. The position peaked at $1.76M in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

Jackson Creek Investment Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Jackson Creek Investment Advisors sold 70,296 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $1.76M.
Jackson Creek Investment Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Jackson Creek Investment Advisors's Kiniksa Pharmaceuticals position peaked at $1.76M in Q3 2024.
160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Jackson Creek Investment Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.